Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IRAK4 | Q9NWZ3 | 6/20 | 0.41 |
| ▸ | PIM1 | P11309 | 9/20 | 0.40 |
| ▸ | PIM2 | Q9P1W9 | 5/20 | 0.40 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 3/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.35 |
| ▸ | RET | P07949 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16935968 | 0.80 | TGFBR1 (0.40) | IRAK4NTRK1TGFBR1 | |
| SCHEMBL19816178 | 0.77 | PIM1 (0.43) | IRAK4PIM1PIM2PIM3NTRK1 | |
| SCHEMBL16946714 | 0.74 | IRAK4 (0.42) | IRAK4NTRK1TGFBR1 | |
| SCHEMBL16935995 | 0.72 | SCN9A (0.41) | IRAK4NTRK1TGFBR1 | |
| SCHEMBL19816197 | 0.70 | NTRK1 (0.42) | IRAK4PIM1PIM2PIM3NTRK1 | |
| SCHEMBL16936085 | 0.67 | NTRK1 (0.45) | IRAK4NTRK1TGFBR1 | |
| SCHEMBL21996890 | 0.66 | IRAK4 (0.46) | IRAK4PIM1PIM2PIM3NTRK1 | |
| SCHEMBL18208666 | 0.66 | JAK2 (0.50) | IRAK4TGFBR1RET | |
| SCHEMBL23037390 | 0.66 | NTRK1 (0.59) | NTRK1 | |
| SCHEMBL23037392 | 0.66 | NTRK1 (0.59) | NTRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10618912-B2 | Diaryl macrocycles as modulators of protein kinases | Turning Point Therapeutics, Inc. (US) | 2020-04-14 | — | — | US | disclosed |
| US-20190169207-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | Turning Point Therapeutics, Inc. | 2019-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190169207-A1 | DIARYL MACROCYCLES AS MODULATORS OF PROTEIN KINASES | MAP3K20, LCK, DAPK2 | IRAK4 340/4885PIM1 1181/4885PIM2 1048/4885 |
| US-10618912-B2 | Diaryl macrocycles as modulators of protein kinases | MAP3K20, LCK, MAP3K1 | IRAK4 343/4885PIM1 1081/4885PIM2 1010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.